Influence of the interval between transcatheter arterial embolization and radiofrequency ablation on the treatment outcome of small hepatocellular carcinoma

Yu SUN; Honghai ZHANG; Jiang LONG; Shoupeng SHENG; Jiasheng ZHENG; Yonghong ZHANG

doi:10.3969/j.issn.1001-5256.2022.10.016

Volume 38 Issue 10

Oct. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(10): 2286-2289

PDF( 1758 KB)

Influence of the interval between transcatheter arterial embolization and radiofrequency ablation on the treatment outcome of small hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2022.10.016

Center of Interventional Oncology and Liver Diseases, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China

Research funding:

Scientific Research and Cultivation Plan of Beijing Municipal Hospitals (PX2022067);

Natural Science Foundation of Beijing Municipality (7191004);

Beijing Key Laboratory of Biomarkers for Infectious Diseases (BZ0373)

More Information

Corresponding author: ZHANG Yonghong, 13810108505@163.com(ORCID: 0000-0002-1357-7891)
Received Date: 2022-03-02
Accepted Date: 2022-04-05
Published Date: 2022-10-20

Abstract

Abstract

Objective To investigate the influence of the interval between transcatheter arterial embolization (TAE) and radiofrequency ablation on the treatment outcome of small hepatocellular carcinoma. Methods A total of 70 patients with hepatocellular carcinoma who received treatment in Beijing YouAn Hospital, Capital Medical University, from January 2019 to June 2020 were enrolled and divided into observation group (radiofrequency ablation was performed on the day or the second day of TAE) and control group (radiofrequency ablation was performed at 1-2 weeks after TAE) using a random number table, with 35 patients in each group. The independent samples t-test was used for comparison of continuous data between two groups, and the paired t-test was used for comparison of observation indicators before and after surgery; the chi-square test was used for comparison of categorical data between two groups. Results The observation group had a significantly shorter length of hospital stay than the control group (7.80±2.76 days vs 14.31±2.19 days, t=-10.93, P < 0.001). There were no significant differences between the observation group and the control group in complete ablation rate (95.12% vs 95.00%, χ²=0.001, P=0.980), incidence rate of adverse reactions (25.71% vs 20.00%, χ²=0.324, P=0.569), and 1-year recurrence rate (11.43% vs 14.29%, χ²=0.128, P=0.721), and there were also no significant differences in laboratory markers between the two groups before and after treatment (all P > 0.05). Conclusion TAE combined with sequential radiofrequency ablation at a short interval is safe and effective in the treatment of small hepatocellular carcinoma and can significantly shorten the length of hospital stay and reduce hospital costs, and therefore, it holds promise for clinical application.
- Carcinoma, Hepatocellular,
- Embolization, Therapeutic,
- Local Ablation,
- Treatment Outcome

FullText(HTML)

References(14)

References

[1]	BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
[2]	ZHOU R, LI S, WAN WJ, et al. Comparison of clinical prognosis between surgical resection and local thermal ablation for small liver cancer[J/CD]. Chin J Hepat Surg (Electronic Edition), 2021, 10(3): 258-262. DOI: 10.3877/cma.j.issn.2095-3232.2021.03.006. 周瑞, 李珊, 万文军, 等. 手术切除与局部热消融治疗小肝癌预后比较[J/CD]. 中华肝脏外科手术学电子杂志, 2021, 10(3): 258-262. DOI: 10.3877/cma.j.issn.2095-3232.2021.03.006.
[3]	LIU YY, LAI JX. Minimally invasive interventional therapy for liver cancer[J/CD]. Chin J Hepat Surg: Electronic Edition, 2020, 9(3): 201-205. DOI: 10.3877/cma.j.issn.2095-3232.2020.03.001. 刘允怡, 赖俊雄. 肝癌微创介入治疗[J/CD]. 中华肝脏外科手术学电子杂志, 2020, 9(3): 201-205. DOI: 10.3877/cma.j.issn.2095-3232.2020.03.001.
[4]	KIM JW, KIM JH, WON HJ, et al. Hepatocellular carcinomas 2-3 cm in diameter: transarterial chemoembolization plus radiofrequency ablation vs. radiofrequency ablation alone[J]. Eur J Radiol, 2012, 81(3): e189-e193. DOI: 10.1016/j.ejrad.2011.01.122.
[5]	XIONG K, BAI F, CHEN DN, et al. Comparison of the effcacy and safety of the combined treatment of transcatheter arterial chemoembolization and radiofrequency ablation with transcatheter arterial chemoembolization or radiofrequency ablation treatment alone in patients with primary hepatic carcinoma in China[J]. Chin Health Resources, 2018, 21(3): 271-274, 279. DOI: 10.13688/j.cnki.chr.2018.17765. 熊琨, 白飞, 陈丹妮, 等. 中国原发性肝癌肝动脉化疗栓塞术和射频消融联合治疗与单独治疗的有效性和安全性比较[J]. 中国卫生资源, 2018, 21(3): 271-274, 279. DOI: 10.13688/j.cnki.chr.2018.17765.
[6]	ZHANG M, HUANG J, XIAO HX, et al. Time node study of sequential treatment of primary hepatocellular carcinoma by hepatic artery embolization chemotherapy combined with microwave ablation guided by ultrasound[J]. J Clin Exp Med, 2021, 20(10): 1080-1083. DOI: 10.3969/j.issn.1671-4695.2021.10.020. 张明, 黄君, 肖华旭, 等. 肝动脉栓塞化疗联合超声引导下微波消融序贯治疗原发性肝癌的时间节点研究[J]. 临床和实验医学杂志, 2021, 20(10): 1080-1083. DOI: 10.3969/j.issn.1671-4695.2021.10.020.
[7]	National Health and Family Planning Commission of the People's Republic of China. Diagnosis, management, and treatment of hepatocellular carcinoma (V2017)[J]. J Clin Hepatol, 2017, 33(8): 1419-1431. DOI: 10.3969/j.issn.1001-5256.2017.08.003. 中华人民共和国国家卫生和计划生育委员会. 原发性肝癌诊疗规范(2017年版)[J]. 临床肝胆病杂志, 2017, 33(8): 1419-1431. DOI: 10.3969/j.issn.1001-5256.2017.08.003.
[8]	CAI DS, ZHU WD, LI Z. Superselective hepatic arterial embolization associated with radiofrequency ablation in treating primary small hepatocellular carcinoma[J]. J Intervent Radiol, 2008, 17(3): 218-219. DOI: 10.3969/j.issn.1008-794X.2008.03.020. 蔡东顺, 朱望东, 李哲. 超选择性肝动脉栓塞与射频消融术联合治疗小肝癌[J]. 介入放射学杂志, 2008, 17(3): 218-219. DOI: 10.3969/j.issn.1008-794X.2008.03.020.
[9]	WANG Y, MA L, SHENG S, et al. Combination therapy of TACE and CT-guided partial hepatic segment ablation for liver cancer[J]. Minim Invasive Ther Allied Technol, 2018, 27(6): 355-364. DOI: 10.1080/13645706.2018.1462833.
[10]	OH JH, SINN DH, CHOI GS, et al. Comparison of outcome between liver resection, radiofrequency ablation, and transarterial therapy for multiple small hepatocellular carcinoma within the Milan criteria[J]. Ann Surg Treat Res, 2020, 99(4): 238-246. DOI: 10.4174/astr.2020.99.4.238.
[11]	SI ZM, WANG GZ, QIAN S, et al. Combination therapies in the management of large (≥5 cm) hepatocellular carcinoma: Microwave ablation immediately followed by transarterial chemoembolization[J]. J Vasc Interv Radiol, 2016, 27(10): 1577-1583. DOI: 10.1016/j.jvir.2016.02.014.
[12]	JIN H, WANG H, LI G, et al. Risk factors for early postoperative recurrence in single and small hepatitis B virus-associated primary hepatocellular carcinoma[J]. J Int Med Res, 2020, 48(10): 300060520961260. DOI: 10.1177/0300060520961260.
[13]	GUO WP, WANG J, GUAN YW, et al. TACE combined with microwave ablation versus radical surgical resection for the treatment of small HCC: a comparison study[J]. J Intervent Radiol, 2019, 28(7): 642-646. DOI: 10.3969/j.issn.1008-794X.2019.07.007. 郭玮平, 王杰, 管一伟, 等. 肝动脉化疗栓塞联合微波消融与外科根治性切除治疗小肝癌的对照研究[J]. 介入放射学杂志, 2019, 28(7): 642-646. DOI: 10.3969/j.issn.1008-794X.2019.07.007.
[14]	LI Z, HAO D, JIAO D, et al. Transcatheter arterial chemoembolization combined with simultaneous cone-beam computed tomography-guided microwave ablation in the treatment of small hepatocellular carcinoma: Clinical experiences from 50 procedures[J]. Acad Radiol, 2021, 28(Suppl 1): s64-s70. DOI: 10.1016/j.acra.2020.08.036.

Relative Articles

[1]	Jun GAO, Huan CHEN, Yan LIU, Feng ZHANG, Yuzheng ZHUGE. Effect of interleukin-22 on hepatic stellate cell activation and its mechanism[J]. Journal of Clinical Hepatology, 2024, 40(11): 2229-2237. doi: 10.12449/JCH241116
[2]	Yekai ZONG, Jiangkai LIU. The physiological and pathological role of amyloid protein in the liver[J]. Journal of Clinical Hepatology, 2023, 39(11): 2730-2737. doi: 10.3969/j.issn.1001-5256.2023.11.031
[3]	Feiyan LI, Minggang WANG, Dewen MAO, Xiongbin GUI. Role of gasdermin D in the pathological progression of liver diseases[J]. Journal of Clinical Hepatology, 2023, 39(3): 707-712. doi: 10.3969/j.issn.1001-5256.2023.03.035
[4]	Xiaolu ZHAO, Chunyan ZHANG, Xiaoyang GAO, Yuehong MA. Mechanism of action of the Hippo/YAP pathway in the development and progression of liver fibrosis[J]. Journal of Clinical Hepatology, 2022, 38(7): 1654-1657. doi: 10.3969/j.issn.1001-5256.2022.07.037
[5]	Xin LUO, Ying QU, Xiaobo CAI, Lungen LU. Effects of antiviral therapy on the reversal of liver fibrosis[J]. Journal of Clinical Hepatology, 2022, 38(11): 2596-2598. doi: 10.3969/j.issn.1001-5256.2022.11.032
[6]	Wenzheng YOU, Wanlei REN, Shiying XUAN, Doudou HU. Association between intrahepatic bile duct alterations and liver fibrosis[J]. Journal of Clinical Hepatology, 2022, 38(1): 187-190. doi: 10.3969/j.issn.1001-5256.2022.01.032
[7]	Fan Chang, Wu FuRong, Zhang JiaFu, Jiang Hui. Role of pyroptosis in the pathogenesis of hepatic fibrosis[J]. Journal of Clinical Hepatology, 2020, 36(5): 1138-1140. doi: 10.3969/j.issn.1001-5256.2020.05.042
[8]	YANG Jing, GAO Hong, ZHAO YaoWei, WANG Rui. Role of liver sinusoidal endothelial cells in the pathogenesis of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(11): 2601-2605. doi: 10.3969/j.issn.1001-5256.2020.11.046
[9]	Geng WenJing, Liu Hui, Ding HuiGuo. Recent advances in drug-induced liver injury: Potential mechanisms, pathological features, and biomarkers[J]. Journal of Clinical Hepatology, 2019, 35(4): 925-929. doi: 10.3969/j.issn.1001-5256.2019.04.049
[10]	Jiang LiNa, Zhao JingMin. A clinical trial on the follow-up of nonalcoholic fatty liver disease: An evaluation of pathological endpoint[J]. Journal of Clinical Hepatology, 2018, 34(12): 2505-2508. doi: 10.3969/j.issn.1001-5256.2018.12.004
[11]	Pan Jing, Pan WenTing, Wu LiHui. Expression and significance of Th22 cells and its functional factor interleukin-22 in mice with autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2018, 34(8): 1745-1749. doi: 10.3969/j.issn.1001-5256.2018.08.030
[12]	Wang BingQiong, Sun YaMeng, You Hong, Shao Chen, Wang TaiLing. Pathological assessment of liver fibrosis regression[J]. Journal of Clinical Hepatology, 2017, 33(3): 435-437. doi: 10.3969/j.issn.1001-5256.2017.03.007
[13]	Bao SuXia, Zheng JianMing, Shi GuangFeng. Research progress in association between interleukin-23 and liver diseases[J]. Journal of Clinical Hepatology, 2016, 32(2): 393-396. doi: 10.3969/j.issn.1001-5256.2016.02.044
[14]	Wang Wei, Zhao RongRong, Yang XiaoFei, Huang ZhangXing, Lian JianQi, Wang JiuPing, Zhang Ye. Influence of Notch signaling pathway on interleukin-22 secreted by CD4~+T cells in patients with hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(7): 1315-1318. doi: 10.3969/j.issn.1001-5256.2016.07.020
[15]	Wu Qin, Meng FanPing, Ma XueMei, Jin Bo, Shen LiJun, Wu LiBing, Chu JinDong, Lai WenHui, Han JingJing, Li HanWei. Analysis of association between different HCV genotypes and serum interleukin-17, interleukin-6, and vitamin D in patients with HCV-related cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(11): 1849-1852. doi: 10.3969/j.issn.1001-5256.2015.11.019
[16]	Guan HaiTao, Zhao JinLi, Tang Rui, Sun LinLin. IL-17 promotes expression of fibrosis-related factors in hepatic stellate cells[J]. Journal of Clinical Hepatology, 2013, 29(5): 370-374.
[17]	Wang WeiBin, Zhu YouFu. A brief discussion on pathogenesis of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2013, 29(11): 805-809. doi: 10.3969/j.issn.1001-5256.2013.11.002
[18]	Sha XiuJuan, Xin GuiJie, Jin MeiShan, Chi TouMei, Niu JunQi. Pay much attention to the clinical application of pathological examination of liver biopsy in the diagnosis and treatment of liver disease[J]. Journal of Clinical Hepatology, 2012, 28(3): 223-226.

Supplements(0)

Cited By

Cited by

Periodical cited type(4)

1.	翟飞，闫菊，何嘉宾，张庆勇，吴燕. 开腹联合肝脏离断和门静脉结扎二步肝切除术治疗原发性肝癌疗效及对患者肝功能指标、术后生存情况的影响. 临床和实验医学杂志. 2023(04): 375-379 .
2.	尚敏杰，张军港，顾宗庭，魏芳强，陶然，吴国清，文阳，沈坚，唐雨琪. 免疫联合靶向治疗预防肝细胞癌行ALPPS术后复发的临床疗效. 中华消化外科杂志. 2023(02): 281-285 .
3.	郭佳胤，徐杰，刘作金. 腹腔镜下ALPPS右半肝切除一例（附视频）. 中华肝脏外科手术学电子杂志. 2023(03): 345-347 .
4.	杨雄威，高晓杰，覃日利，张新晨. ALPPS临床应用及术式改良. 中华肝脏外科手术学电子杂志. 2022(04): 347-350 .

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (462) PDF downloads(38)

Influence of the interval between transcatheter arterial embolization and radiofrequency ablation on the treatment outcome of small hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2022.10.016